Prokineticin 2 relieves hypoxia/reoxygenation-induced injury through activation of Akt/mTOR pathway in H9c2 cardiomyocytes

References

• Hartley A, Marshall DC, Salciccioli JD, et al. Trends in mortality from ischemic heart disease and cerebrovascular disease in Europe: 1980 to 2009. Circulation. 2016;133(20):1916–1926.
   PubMed Web of Science ®Google Scholar
• Xue-Juan W, Hao W, Cai-Ying G, et al. Impact of an intelligent chronic disease management system on patients with type 2 diabetes mellitus in a Beijing community. BMC Health Serv Res. 2018;18(1):821.
   PubMedGoogle Scholar
• Araszkiewicz A, Grygier M, Lesiak M, et al. The impact of ischemia-reperfusion injury on the effectiveness of primary angioplasty in ST-segment elevation myocardial infarction. PWKI. 2013;9:275–281.
   Google Scholar
• Ansari J, Kaur G, Gavins F. Therapeutic potential of annexin A1 in ischemia reperfusion injury. IJMS. 2018;19(4):1211.
   Google Scholar
• Lin DC, Bullock CM, Ehlert FJ, et al. Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor. J Biol Chem. 2002;277(22):19276–19280.
   PubMed Web of Science ®Google Scholar
• Giannini E, Lattanzi R, Nicotra A, et al. The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. Proc Natl Acad Sci USA. 2009;106(34):14646–14651.
   PubMed Web of Science ®Google Scholar
• Monnier J, Samson M. Prokineticins in angiogenesis and cancer. Cancer Lett. 2010;296(2):144–149.
   PubMed Web of Science ®Google Scholar
• Negri L, Lattanzi R, Giannini E, et al. Bv8, the amphibian homologue of the mammalian prokineticins, modulates ingestive behaviour in rats. Br J Pharmacol. 2004;142(1):181–191.
   PubMed Web of Science ®Google Scholar
• Landucci E, Lattanzi R, Gerace E, et al. Prokineticins are neuroprotective in models of cerebral ischemia and ischemic tolerance in vitro. Neuropharmacology. 2016;108:39–48.
   PubMed Web of Science ®Google Scholar
• Hu WP, Zhang C, Li JD, et al. Impaired pain sensation in mice lacking prokineticin 2. Mol Pain. 2006;2:35.
   PubMed Web of Science ®Google Scholar
• Urayama K, Guilini C, Messaddeq N, et al. The prokineticin receptor-1 (GPR73) promotes cardiomyocyte survival and angiogenesis. FASEB J. 2007;21(11):2980–2993.
   PubMed Web of Science ®Google Scholar
• Li C, Zhang Y, Wang Q, et al. Dragon's blood exerts cardio-protection against myocardial injury through PI3K-Akt-mTOR signaling pathway in acute myocardial infarction mice model. J Ethnopharmacol. 2018;227:279–289.
   PubMed Web of Science ®Google Scholar
• Al Rajoub B, Noureddine S, El Chami S, et al. The prognostic value of a new left bundle branch block in patients with acute myocardial infarction: A systematic review and meta-analysis. Heart Lung. 2017;46(2):85–91.
   PubMed Web of Science ®Google Scholar
• Yu P, Zhang J, Yu S, et al. Protective effect of sevoflurane postconditioning against cardiac ischemia/reperfusion injury via ameliorating mitochondrial impairment, oxidative stress and rescuing autophagic clearance. PLoS One. 2015;10(8):e0134666.
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhou M, Li C, et al. MicroRNA-92a inhibition attenuates hypoxia/reoxygenation-induced myocardiocyte apoptosis by targeting Smad7. PLOS One. 2014;9(6):e100298.
   PubMed Web of Science ®Google Scholar
• Baines CP. How and when do myocytes die during ischemia and reperfusion: the late phase. J Cardiovasc Pharmacol Ther. 2011;16(3-4):239–243.
   PubMed Web of Science ®Google Scholar
• de Vries DK, Kortekaas KA, Tsikas D, et al. Oxidative damage in clinical ischemia/reperfusion injury: A reappraisal. Antioxid Redox Signal. 2013;19(6):535–545.
   PubMed Web of Science ®Google Scholar
• Khurana R, Simons M, Martin JF, et al. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation. 2005;112(12):1813–1824.
   PubMed Web of Science ®Google Scholar
• Urban JD, Clarke WP, von Zastrow M, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther. 2007;320(1):1–13.
   PubMed Web of Science ®Google Scholar
• Nebigil CG. Prokineticin is a new linker between obesity and cardiovascular diseases. Front Cardiovasc Med. 2017;4:20.
   PubMed Web of Science ®Google Scholar
• LeCouter J, Lin R, Tejada M, et al. The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: localization of Bv8 receptors to endothelial cells. Proc Natl Acad Sci USA. 2003;100(5):2685–2690.
   PubMed Web of Science ®Google Scholar
• Kisliouk T, Podlovni H, Spanel-Borowski K, et al. Prokineticins (endocrine gland-derived vascular endothelial growth factor and BV8) in the bovine ovary: expression and role as mitogens and survival factors for corpus luteum-derived endothelial cells. Endocrinology. 2005;146(9):3950–3958.
   PubMed Web of Science ®Google Scholar
• Guilini C, Urayama K, Turkeri G, et al. Divergent roles of prokineticin receptors in the endothelial cells: angiogenesis and fenestration. Am J Physiol Heart Circ Physiol. 2010;298(3):H844–852.
   PubMed Web of Science ®Google Scholar
• Cheng MY, Lee AG, Culbertson C, et al. Prokineticin 2 is an endangering mediator of cerebral ischemic injury. Proc Natl Acad Sci USA. 2012;109(14):5475–5480.
   PubMed Web of Science ®Google Scholar
• Karar J, Maity A. PI3K/Akt/mTOR pathway in angiogenesis. Front Mol Neurosci. 2011;4:51.
   PubMed Web of Science ®Google Scholar
• Li C, Tian J, Li G, et al. Asperosaponin VI protects cardiac myocytes from hypoxia-induced apoptosis via activation of the PI3K/Akt and CREB pathways. Eur J Pharmacol. 2010;649(1-3):100–107.
   PubMed Web of Science ®Google Scholar
• Qin L, Fan S, Jia R, et al. Ginsenoside Rg1 protects cardiomyocytes from hypoxia-induced injury through the PI3K/Akt/mTOR pathway. Pharmazie. 2018;73(6):349–355.
   PubMed Web of Science ®Google Scholar
• Huang Z, Wu S, Kong F, et al. MicroRNA-21 protects against cardiac hypoxia/reoxygenation injury by inhibiting excessive autophagy in H9c2 cells via the Akt/mTOR pathway. J Cell Mol Med. 2017;21(3):467–474.
   PubMed Web of Science ®Google Scholar
• Xu Y, Gu Q, Tang J, et al. Substance P attenuates hypoxia/reoxygenation-induced apoptosis via the Akt signalling pathway and the NK1-receptor in H9C2cells. Heart Lung Circ. 2018;27(12):1498–1506.
   PubMed Web of Science ®Google Scholar
• Chen M, Zhang M, Zhang X, et al. Limb ischemic preconditioning protects endothelium from oxidative stress by enhancing Nrf2 translocation and upregulating expression of antioxidases. PLoS One. 2015;10(6):e0128455.
   PubMed Web of Science ®Google Scholar
• Duan J, Guan Y, Mu F, et al. Protective effect of butin against ischemia/reperfusion-induced myocardial injury in diabetic mice: involvement of the AMPK/GSK-3β/Nrf2 signaling pathway. Sci Rep. 2017;7(1):41491.
   PubMedGoogle Scholar
• Yao H, Han X, Han X. The cardioprotection of the insulin-mediated PI3K/Akt/mTOR signaling pathway. Am J Cardiovasc Drugs. 2014;14(6):433–442.
   PubMed Web of Science ®Google Scholar